One in 5 Covid-19 patients develop mental illness problems within three months
One in 5 Covid-19 patients develop mental illness problems within three months

One in 5 Covid-19 patients develop mental illness problems within three months

A major new study has found that one in five patients affected by Covid-19 develops mental illness problems within three months.

Those problems include anxiety, depression and insomnia as well as dementia.

“People have been worried that COVID-19 survivors will be at greater risk of mental health problems, and our findings show this to be likely,” said Paul Harrison, a professor of psychiatry at Britain’s Oxford University.

The study looked at data and health records from 69 million people in America, including 62,000 cases of those with Covid-19.

The Lancet Psychiatry study analysed electronic health records of 69 million people in the United States, including more than 62,000 cases of COVID-19.

The study found that one in five Covid-19 patients would suffer from anxiety, depression or insomnia within 90 days. This was double the percentage for those without Covid-19.

Although, let’s be honest, we’ve all probably suffered from those first three symptoms at some point this year, it’s been relentless!

The results echo the findings of Long Covid, a condition that affects sufferers for weeks and months after the initial illness.

“COVID-19 affects the central nervous system, and so might directly increase subsequent disorders. But this research confirms that is not the whole story, and that this risk is increased by previous ill health,” added Simon Wessely, regius professor of psychiatry at King’s College London.

New vaccine has 90% success rate

A major new Coronavirus vaccine from Pfizer and BioNTech has a 90% success rate and could be deployed by the end of the year.

The vaccine is in the third and final stage of testing. And 90% of those with the vaccine were protected from Coronavirus within 28 days of having the jab. The trial involved 43,538 volunteers, with just 94 people developing Coronavirus after the jab and none with serious health concerns.

“Today is a great day for science and humanity. The first set of results from our Phase 3 Covid-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Pfizer chairman and chief executive Dr Albert Bourla.

Facebook Comments